

Metabolic signatures and incident diabetes in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)



Jin Choul Chai¹, Jun Li², Bing Yu³, Carmen R Isasi¹, Daniela Sotres-Alvarez⁴, Tasneem Khambaty⁵, Krista M Perreira⁴, Jianwen Cai⁴, Linda Van Horn⁶, Marisa J Perera⁷, Denise C Vidot⁷, Sheila F Castaneda⁸, Natalie Mora⁹, Martha Daviglus¹⁰, Robert Kaplan^{1,11}, Eric Boerwinkle^{3,12}, Qibin Qi^{1,2}


Introduction

- Previous metabolomic studies have identified many metabolites associated with diabetes.
- Despite high prevalence of diabetes among US Hispanics/Latinos, metabolomic studies have scarce among the US Hispanic/Latino population.

Objectives

- To identify serum metabolomic signatures associated with risk of diabetes in US Hispanics/Latinos.
- To examine the associations between diabetes-associated metabolites and diet/lifestyle factors in US Hispanics/Latinos.

Study Design



- Sample size: 224 incident diabetes cases, 1786 non cases
- Outcome variables: incident diabetes at SOL visit 2
- American Diabetes Association definition
- Fasting time > 8hr and Fasting glucose ≥ 126 mg/dL
 Fasting time ≤ 8hr and Fasting glucose ≥ 200 mg/dL
- 2h post OGTT ≥ 200 mg/dL
- Hemoglobin (A1C) ≥ 6.5%
- Hellioglobili (AIC) 2 0.
- Self-report medication use
- Exposure variables: 624 known metabolites
- Statistical model: Survey Poisson regression
- **Covariates:** age, gender, household income, education, current smoking, alcohol use, field center, family history of diabetes, Hispanic background, general health variables, medication use, alternative healthy eating index 2010 (AHEI-2010), and total physical activity, BMI, waist and hip ratio, HDL, total cholesterol, systolic blood pressure, diastolic blood pressure.

Results

Table 1. Basic characteristics

	Non-diabetes	Incident diabetes
	(N=1,786)	(N=224)
Age, years	45 (34-53)	50 (46-56)
Female	60 %	62 %
Current smoking	20 %	17 %
Current alcohol use	53 %	47 %
Education > high school	41 %	38 %
Income <\$30,000	60 %	71 %
Lipid-lowering medicine use	5 %	10 %
Antihypertensive medicine use	9 %	17 %
Family history of diabetes	40 %	53 %
Body mass index, kg/m ²	28 (25-32)	31 (28-35)
High density lipoprotein, mg/dL	49 (42-58)	45 (39-52)
Triglycerides, mg/dL	106 (75-153)	142 (101-200)
Systolic blood pressure, mmHg	117 (108-128)	124 (112-134)
Diastolic blood pressure, mmHg	72 (65-79)	77 (70-83)




Figure 1. Overall metabolites polar bar plot and metabolites proportion.

Associations between 624 metabolites and incident diabetes (A) . Data were presented according to supper- and sub-pathways of metabolites. The inner-circle indicated the super-pathways of metabolites included in the analyses. The middle bar plot represents $-\log 10$ P-value of individual metabolites associated with incident diabetes, and 134 significant metabolites are highlighted in red (positive associations) or in blue (inverse association). Metabolites with FDR-adjusted P values ≥ 0.05 were shown in gray. The outer circle indicates 15 sub-pathways which have ≥ 5 significant metabolites, or in which the proportion of significant metabolites $\geq 50\%$.




Figure 2. Network of 134 incident diabetes associated metabolites and Correlation heatmap among sub-network modules.

The correlation heatmap showed partial correlation between 12 network sub-modules. Color indicated correlation coefficient between two modules (A). The network represents the overall correlation network among 134 incident diabetes associated metabolites (B). The colors indicate 12 sub-network modules detected by topological overlap measures, although many of the metabolites within the same super-pathway belong to the same module. The edges indicate a weighted correlation coefficient between each metabolite.

AA indicated amino acids; Carb, carbohydrates; PC, phosphatidylcholine; BCAA, branched-chain amino acid; TRP, tryptophan; MAG, monoacylglycerol; DAG, diacylglycerol; PI, phosphatidylinositol; PE, phosphatidylethanolamine.

Table 2. Poisson regression model on incident diabetes related network sub modules.

Sub pathways No. Of	Ton motobolitos	Model 1		Model 2		
Sub-patriways	metabolites	rop metabolites	Risk ratio (95% CI)	P-value	Risk ratio (95% CI)	P-value
Sphingolipids	8	behenoyl dihydrosphingomyelin (d18:0/22:0)	1.70 (1.42-2.02)	<0.001	1.41 (1.18-1.67)	<0.001
PC, PI (20:4)	4	1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)	1.46 (1.19-1.79)	< 0.001	1.30 (1.07-1.57)	0.013
MAG, DAG	9	1-palmitoleoylglycerol (16:1)	1.56 (1.33-1.82)	< 0.001	1.31 (0.87-1.96)	0.198
PC, PI	10	1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)	1.63 (1.36-1.95)	< 0.001	1.40 (1.12-1.74)	0.005
PE	10	1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	1.52 (1.27-1.83)	< 0.001	1.21 (0.95-1.54)	0.125
Androgenic Steroids	6	androstenediol (3beta,17beta) disulfate (1)	1.47 (1.19-1.82)	< 0.001	1.30 (1.04-1.62)	0.026
BCAA/TRP catabolism	25	urate	2.03 (1.65-2.50)	< 0.001	1.57 (1.26-1.95)	< 0.001
BCAA products	13	2-hydroxy-3-methylvalerate	2.04 (1.60-2.58)	< 0.001	1.68 (1.29-2.18)	< 0.001
Glycine	4	glycine	0.61 (0.51-0.74)	< 0.001	0.75 (0.61-0.93)	0.013
Hydrocarbon derivative	9	ribitol	1.61 (1.35-1.91)	< 0.001	1.33 (1.11-1.60)	0.005
Energy related	9	pyruvate	1.93 (1.65-2.24)	< 0.001	1.59 (1.35-1.89)	< 0.001
Food Component	6	oxalate (ethanedioate)	0.66 (0.56-0.77)	<0.001	0.70 (0.59-0.83)	<0.001
	PC, PI (20:4) MAG, DAG PC, PI PE Androgenic Steroids BCAA/TRP catabolism BCAA products Glycine Hydrocarbon derivative Energy related Food Component	Sub-pathways Sphingolipids PC, PI (20:4) MAG, DAG PC, PI PE 10 Androgenic Steroids BCAA/TRP catabolism BCAA products Glycine Hydrocarbon derivative Energy related Food Component Sphingolipids 8 8 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10	Sub-pathwaysMetabolitesTop metabolitesSphingolipids8behenoyl dihydrosphingomyelin (d18:0/22:0)PC, PI (20:4)41-stearoyl-2-arachidonoyl-GPI (18:0/20:4)MAG, DAG91-palmitoleoylglycerol (16:1)PC, PI101-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)PE101-palmitoyl-2-oleoyl-GPE (16:0/18:1)Androgenic Steroids6androstenediol (3beta,17beta) disulfate (1)BCAA/TRP catabolism25urateBCAA products132-hydroxy-3-methylvalerateGlycine4glycineHydrocarbon derivative9ribitolEnergy related9pyruvateFood Component6oxalate (ethanedioate)	Sub-pathways Top metabolites Risk ratio (95% CI) Sphingolipids 8 behenoyl dihydrosphingomyelin (d18:0/22:0) 1.70 (1.42-2.02) PC, PI (20:4) 4 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) 1.46 (1.19-1.79) MAG, DAG 9 1-palmitoleoylglycerol (16:1) 1.56 (1.33-1.82) PC, PI 10 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) 1.63 (1.36-1.95) PE 10 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) 1.52 (1.27-1.83) Androgenic Steroids 6 androstenediol (3beta,17beta) disulfate (1) 1.47 (1.19-1.82) 3CAA/TRP catabolism 25 urate 2.03 (1.65-2.50) BCAA products 13 2-hydroxy-3-methylvalerate 2.04 (1.60-2.58) Glycine 4 glycine 0.61 (0.51-0.74) Hydrocarbon derivative 9 ribitol 1.61 (1.35-1.91) Energy related 9 pyruvate 1.93 (1.65-2.24) Food Component 6 oxalate (ethanedioate) 0.66 (0.56-0.77)	Sub-pathways Top metabolites Risk ratio (95% CI) P-value Sphingolipids 8 behenoyl dihydrosphingomyelin (d18:0/22:0) 1.70 (1.42-2.02) <0.001 PC, PI (20:4) 4 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) 1.46 (1.19-1.79) <0.001 MAG, DAG 9 1-palmitoleoylglycerol (16:1) 1.56 (1.33-1.82) <0.001 PC, PI 10 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) 1.63 (1.36-1.95) <0.001 PE 10 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) 1.52 (1.27-1.83) <0.001 Androgenic Steroids 6 androstenediol (3beta,17beta) disulfate (1) 1.47 (1.19-1.82) <0.001 BCAA/TRP catabolism 25 urate 2.03 (1.65-2.50) <0.001 BCAA products 13 2-hydroxy-3-methylvalerate 2.04 (1.60-2.58) <0.001 Hydrocarbon derivative 9 ribitol 1.61 (1.35-1.91) <0.001 Energy related 9 pyruvate 1.93 (1.65-2.24) <0.001 Food Component 6 oxalate (ethanedioate) 0.66 (0.56-0.77) <0.001	Sub-pathways metabolites Top metabolites Risk ratio (95% CI) P-value Risk ratio (95% CI) Sphingolipids 8 behenoyl dihydrosphingomyelin (d18:0/22:0) 1.70 (1.42-2.02) <0.001 1.41 (1.18-1.67) PC, PI (20:4) 4 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) 1.46 (1.19-1.79) <0.001 1.30 (1.07-1.57) MAG, DAG 9 1-palmitoleoyleyl-GPC (16:0/16:1) 1.56 (1.33-1.82) <0.001 1.31 (0.87-1.96) PC, PI 10 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) 1.63 (1.36-1.95) <0.001 1.40 (1.12-1.74) PE 10 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) 1.52 (1.27-1.83) <0.001 1.21 (0.95-1.54) Androgenic Steroids 6 androstenediol (3beta,17beta) disulfate (1) 1.47 (1.19-1.82) <0.001 1.30 (1.04-1.62) BCAA/TRP catabolism 25 urate 2.03 (1.65-2.50) <0.001 1.57 (1.26-1.95) BCAA products 13 2-hydroxy-3-methylvalerate 2.04 (1.60-2.58) <0.001 1.68 (1.29-2.18) Glycine 4 glycine 0.61 (0.51-0.74) <0.001

Risk ratios (RR) and 95% confidence intervals (CI) of incident diabetes per SD increment of module score, adjusted for age, gender, current smoking, alcohol use, education, income, fasting hour, lipid lowering medication use, antihypertensive medication use, family history of diabetes, Hispanic background, study field center, total physical activity, and AHEI-2010 (Model 1); and further adjusted for BMI, waist to hip ratio, HDL-cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure (Model 2). BCAA, branched-chain amino acid; DAG, Diacylglycerol; MAG, Monoacylglycerol; PC indicates Phosphatidylcholine; PE, Phosphatidylethanolamine; PI, Phosphatidylinositol; TRP, tryptophan.




Figure 3. Correlation between 12 modules and diabetes risk factors.

Results were partial Pearson correlation heatmap with adjustment for age, gender and Hispanic background. The y-axis indicated risk factors of diabetes and x-axis indicated metabolomic sub-modules.




Figure 4. Association between 12 sub-modules and dietary/lifestyle factors.

Results were survey linear regression with adjustment for age, gender, current smoking, alcohol use, education, income, fasting hour, lipid lowering medication use, antihypertensive medication use, family history of diabetes, Hispanic background, study field center, total physical activity, and AHEI-2010. Color indicated effect size. *P < 0.05, **P < 0.01, ***P < 0.001

Affiliations

- 1. Albert Einstein College of Medicine, Bronx, NY
- Harvard T.H. Chan School of Public Health, Boston, MA
 The University of Texas Health Science Center, Houston, TX
- 4. University of North Carolina, Chapel Hill, NC5. University of Maryland Baltimore County (UMBC), Baltimore, MD
- 6. Feinberg School of Medicine, Chicago, IL
- 7. University of Miami, Coral Gables, FL 8. San Diego State University, San Diego, CA
- 9. NIH, Bethesda, MD
- 10. University of Illinois, Chicago, IL 11. Fred Hutchinson Cancer Research Center, Seattle, WA
- 12. Baylor College of Medicine, Houston, TX

Conclusions

- In a six-year follow-up study, we identified multiple metabolites associated with risk of diabetes in a large cohort of US Hispanics/Latinos.
- A large number of metabolites are involved in known metabolic pathways (e.g., BCAA, ceramides, glucose metabolism) which have been associated with insulin resistance and diabetes.
- Six metabolites in a food component module were associated with lower risk of diabetes and healthier diet.
- Six metabolites in an androgenic steroid module were associated higher risk of diabetes.

contact: Jin Choul Chai jin.chai@einsteinmed.org Investigator's Study Website:

www.cscc.unc.edu/hchs

Funded by:

- ided by:
- National Heart, Lung and Blood Institute
- National Institute on Deafness and Other Communication Disorders
- National Institute on Deafness and Other Communication Disorders

 National Institute of Dental and Craniofacial Research
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Neurological Disorders and Stroke
 NIH Institution-Office of Dietary Supplements

